These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
635 related articles for article (PubMed ID: 36120776)
1. A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias. Bolsewig K; Hok-A-Hin YS; Sepe FN; Boonkamp L; Jacobs D; Bellomo G; Paoletti FP; Vanmechelen E; Teunissen CE; Parnetti L; Willemse EAJ J Alzheimers Dis; 2022; 90(1):363-380. PubMed ID: 36120776 [TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias. Baiardi S; Quadalti C; Mammana A; Dellavalle S; Zenesini C; Sambati L; Pantieri R; Polischi B; Romano L; Suffritti M; Bentivenga GM; Randi V; Stanzani-Maserati M; Capellari S; Parchi P Alzheimers Res Ther; 2022 Oct; 14(1):153. PubMed ID: 36221099 [TBL] [Abstract][Full Text] [Related]
3. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders. Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027 [TBL] [Abstract][Full Text] [Related]
4. Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies. Bolsewig K; van Unnik AAJM; Blujdea ER; Gonzalez MC; Ashton NJ; Aarsland D; Zetterberg H; Padovani A; Bonanni L; Mollenhauer B; Schade S; Vandenberghe R; Poesen K; Kramberger MG; Paquet C; Bousiges O; Cretin B; Willemse EAJ; Teunissen CE; Lemstra AW; Neurology; 2024 Jun; 102(12):e209418. PubMed ID: 38830138 [TBL] [Abstract][Full Text] [Related]
5. Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy. Chouliaras L; Thomas A; Malpetti M; Donaghy P; Kane J; Mak E; Savulich G; Prats-Sedano MA; Heslegrave AJ; Zetterberg H; Su L; Rowe JB; O'Brien JT J Neurol Neurosurg Psychiatry; 2022 Jun; 93(6):651-658. PubMed ID: 35078917 [TBL] [Abstract][Full Text] [Related]
6. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort. Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D; Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532 [TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study. Abu-Rumeileh S; Mometto N; Bartoletti-Stella A; Polischi B; Oppi F; Poda R; Stanzani-Maserati M; Cortelli P; Liguori R; Capellari S; Parchi P J Alzheimers Dis; 2018; 66(2):551-563. PubMed ID: 30320576 [TBL] [Abstract][Full Text] [Related]
8. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration. Ishiki A; Kamada M; Kawamura Y; Terao C; Shimoda F; Tomita N; Arai H; Furukawa K J Neurochem; 2016 Jan; 136(2):258-61. PubMed ID: 26485083 [TBL] [Abstract][Full Text] [Related]
9. Plasma biomarkers of amyloid, tau, axonal, and neuroinflammation pathologies in dementia with Lewy bodies. Vrillon A; Bousiges O; Götze K; Demuynck C; Muller C; Ravier A; Schorr B; Philippi N; Hourregue C; Cognat E; Dumurgier J; Lilamand M; Cretin B; Blanc F; Paquet C Alzheimers Res Ther; 2024 Jul; 16(1):146. PubMed ID: 38961441 [TBL] [Abstract][Full Text] [Related]
10. Blood Neurofilament Light Chain in Different Types of Dementia. Gu L; Shu H; Wang Y; Wang P Curr Alzheimer Res; 2023; 20(3):149-160. PubMed ID: 37264656 [TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of isolated plasma biomarkers and its combination in neurodegenerative dementias: A multicenter cohort study. Chen Y; Wang Y; Tao Q; Lu P; Meng F; Zhuang L; Qiao S; Zhang Y; Luo B; Liu Y; Peng G Clin Chim Acta; 2024 May; 558():118784. PubMed ID: 38588788 [TBL] [Abstract][Full Text] [Related]
12. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic. Shea YF; Ha J; Chu LW Psychogeriatrics; 2015 Dec; 15(4):235-41. PubMed ID: 25533477 [TBL] [Abstract][Full Text] [Related]
13. Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer's disease and frontotemporal dementia. Das S; Goossens J; Jacobs D; Dewit N; Pijnenburg YAL; In 't Veld SGJG; Teunissen CE; Vanmechelen E Alzheimers Res Ther; 2023 Mar; 15(1):62. PubMed ID: 36964594 [TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. Paterson RW; Slattery CF; Poole T; Nicholas JM; Magdalinou NK; Toombs J; Chapman MD; Lunn MP; Heslegrave AJ; Foiani MS; Weston PSJ; Keshavan A; Rohrer JD; Rossor MN; Warren JD; Mummery CJ; Blennow K; Fox NC; Zetterberg H; Schott JM Alzheimers Res Ther; 2018 Mar; 10(1):32. PubMed ID: 29558979 [TBL] [Abstract][Full Text] [Related]
15. The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias. Abu-Rumeileh S; Capellari S; Stanzani-Maserati M; Polischi B; Martinelli P; Caroppo P; Ladogana A; Parchi P Alzheimers Res Ther; 2018 Jan; 10(1):3. PubMed ID: 29368621 [TBL] [Abstract][Full Text] [Related]
16. CSF placental growth factor - a novel candidate biomarker of frontotemporal dementia. Hansson O; Santillo AF; Meeter LH; Nilsson K; Landqvist Waldö M; Nilsson C; Blennow K; van Swieten JC; Janelidze S Ann Clin Transl Neurol; 2019 May; 6(5):863-872. PubMed ID: 31139684 [TBL] [Abstract][Full Text] [Related]
17. Systematic Assessment of 10 Biomarker Candidates Focusing on α-Synuclein-Related Disorders. Schulz I; Kruse N; Gera RG; Kremer T; Cedarbaum J; Barbour R; Zago W; Schade S; Otte B; Bartl M; Hutten SJ; Trenkwalder C; Mollenhauer B Mov Disord; 2021 Dec; 36(12):2874-2887. PubMed ID: 34363416 [TBL] [Abstract][Full Text] [Related]
18. Diagnostic Performance and Clinical Applicability of Blood-Based Biomarkers in a Prospective Memory Clinic Cohort. Sarto J; Ruiz-García R; Guillén N; Ramos-Campoy Ó; Falgàs N; Esteller D; Contador J; Fernández G; González Y; Tort-Merino A; Juncà-Parella J; Bosch B; Borrego-Écija S; Molina-Porcel L; Castellví M; Vergara M; Antonell A; Augé JM; Naranjo L; Sanchez-Valle R; Lladó A; Balasa M Neurology; 2023 Feb; 100(8):e860-e873. PubMed ID: 36450604 [TBL] [Abstract][Full Text] [Related]